Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why LeMaitre (LMAT) Stock Is Down Today

September 03, 2025 at 14:46 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

LMAT Cover Image

What Happened?

Shares of medical device company LeMaitre Vascular (NASDAQ: LMAT) fell 2.2% in the afternoon session after the stock traded lower amid broader market weakness. U.S. stock markets began September trading on a negative note, due to concerns over tariffs and rising U.S. sovereign bond yields, which dented investor sentiment. The downward pressure appeared to continue into Wednesday's session, which saw mixed trading. While the tech-heavy Nasdaq showed gains, the Dow Jones Industrial Average was trading in negative territory. The healthcare sector, to which LeMaitre belongs, has also been facing pressure from factors like rising operational costs. In the absence of any company-specific news, the stock's dip seems to be influenced by these wider market and sector headwinds.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy LeMaitre? Access our full analysis report here, it’s free.

What Is The Market Telling Us

LeMaitre’s shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The previous big move we wrote about was 28 days ago when the stock gained 9.5% on the news that the company reported better-than-expected second-quarter financial results and raised its full-year outlook. The medical device maker reported second-quarter earnings per share of $0.60 on revenue of $64.2 million, which beat Wall Street's expectations. The company's sales jumped 15% from the previous year, pushed by higher prices and a 7% increase in the number of products sold. Strong international sales for its Artegraft product also contributed to the growth. Looking ahead, LeMaitre lifted its full-year 2025 revenue forecast to $251 million and increased its earnings guidance, signaling management's confidence in continued strong performance.

LeMaitre is up 2.4% since the beginning of the year, but at $93.65 per share, it is still trading 13.3% below its 52-week high of $107.97 from November 2024. Investors who bought $1,000 worth of LeMaitre’s shares 5 years ago would now be looking at an investment worth $2,888.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article